Genmab (United States)

Genmab (United States)

Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund. Derived from Wikipedia licensed CC-BY-SA.

Open Access statistics for Genmab (United States), United States, covering academic research published from 2001 to 2024. Read More.


Open Access Percentage

51%


Total
Publications

460


Total Open
Publications

233


Total
Citations

17K


Open Access
Percentage

51%


Total
Publications

460


Total Open
Publications

233


Total
Citations

17K

Wikipedia

Website

download

Breakdown

24% 19% 6% 51%

Publisher Open

24%

Both

19%

Other Platform Open

6%

Closed

51%

Percentage of Open Access over time

0%10%20%30%40%50%60%70%80%90%100%
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024

Publisher Open

Both

Other Platform Open

Closed

Volume of Open Access over time

0102030405060708090100110Total Publications
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024

Open

Closed

Publisher Open

41%OA Journal

OA Journal 41%

79

Hybrid 23%

45

No Guarantees 36%

70

Other Platform Open

Domain 75%

85

Institution 33%

38

Other Internet 9%

10

Preprint 2%

2

Public 1%

1

Other Platform Locations

Name

Platform Type

Publications

PubMed Central
Domain
85
DOI
Other Internet
10
DANS - Data Archiving and Networked Services
Institution
9
Digital Access to Libraries
Institution
6
University of Southern Denmark - University of Southern Denmark Research Portal
Institution
4
Elsevier - Scopus
Institution
4
University of Groningen / Centre for Information Technology - University of Groningen research database
Institution
3
universiteitleiden.nl OAI-PMH Repository
Institution
3
Griffith University, Queensland, Australia - Griffith Research Online
Institution
3
Alma Mater Studiorum Università di Bologna - Archivio istituzionale della ricerca
Institution
3
1 / 4

Data updated 18 August 2025

Share

Share

Share